[Federal Register Volume 85, Number 182 (Friday, September 18, 2020)]
[Notices]
[Page 58391]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-20594]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-705]


Importer of Controlled Substances Application: Fisher Clinical 
Services, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Fisher Clinical Services, Inc. has applied to be registered as 
an importer of basic class(es) of controlled substances. Refer to 
Supplemental Information listed below for further drugs information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before October 19, 
2020. Such persons may also file a written request for a hearing on the 
application on or before October 19, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for a hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on August 3, 2020, Fisher Clinical Services, Inc., 7554 
Schantz Road, Allentown, Pennsylvania 18106-9032, applied to be 
registered as an importer of the following basic class(es) of 
controlled substances:

------------------------------------------------------------------------
               Controlled  substance                Drug code   Schedule
------------------------------------------------------------------------
Psilocybin........................................       7437          I
Methylphenidate...................................       1724         II
Levorphanol.......................................       9220         II
Noroxymorphone....................................       9668         II
Tapentadol........................................       9780         II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances for 
clinical trials only.
    Approval of permit applications will occur only when the 
registrant's business activity is consistent with what is authorized 
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import 
of the Food and Drug Administration approved or non-approved finished 
dosage forms for commercial sale.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-20594 Filed 9-17-20; 8:45 am]
BILLING CODE P